Evidence map›Paper›PMID 30586569›Full record

ArticleJournal of neuroscience methods2019

Polyethylene glycol (PEG) and other bioactive solutions with neurorrhaphy for rapid and dramatic repair of peripheral nerve lesions by PEG-fusion.

Cameron L Ghergherehchi, Michelle Mikesh, Dale R Sengelaub, David M Jackson, Tyler Smith, Jacklyn Nguyen, Jaimie T Shores, George D Bittner

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of neuroscience methods, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04572906 (Phase 2a, Multicenter, Randomized, Patient and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to SOC in the Treatment of Acute Single Transected Peripheral Nerve Injury Occurring Below the Distal Border of the Brachial Plexus Requiring Surgical Repair.), which is not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04572906 phase2completednot on this mapstarted 2020, after this paper: background citation

Phase 2a, Multicenter, Randomized, Patient and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to SOC in the Treatment of Acute Single Transected Peripheral Nerve Injury Occurring Below the Distal Border of the Brachial Plexus Requiring Surgical Repair.

TypeinterventionalSponsorNeuraptive Therapeutics Inc.Ran2020 to 2024Enrolled51ConditionsPeripheral Nerve InjuriesArmsNTX-001
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. The role of antioxidants in facial nerve injury.Frontiers in molecular biosciences · 2025
    Review
  10. In Vitro Models for Peripheral Nerve Regeneration.Advanced healthcare materials · 2024
    Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Cameron L GhergherehchiDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, 78712, USA. Electronic address: cameronlgh@utexas.edu.
Michelle MikeshDepartment of Neuroscience, University of Texas at Austin, Austin, TX, 78712, USA. Electronic address: mfmikesh@utexas.edu.
Dale R SengelaubDepartment of Psychological and Brain Sciences, Indiana University, Bloomington, IN, 47405, USA. Electronic address: sengelau@indiana.edu.
David M JacksonNeuraptive Therapeutics, Lafayette, CO, USA. Electronic address: david.jackson@neuraptive.com.
Tyler SmithDepartment of Molecular Biosciences, University of Texas at Austin, Austin, TX, 78712, USA. Electronic address: tylersmith128@utexas.edu.
Jacklyn NguyenDepartment of Neuroscience, University of Texas at Austin, Austin, TX, 78712, USA. Electronic address: jacklyn.nguyen@utexas.edu.
Jaimie T ShoresDepartment of Plastic and Reconstructive Surgery, Vascularized Composite Allotransplantation (VCA) Laboratory, Johns Hopkins University School of Medicine, Ross Research Building 749D, 720 Rutland Avenue, Baltimore, MD, 21205, USA. Electronic address: jshores3@jhmi.edu.
George D BittnerDepartment of Neuroscience, University of Texas at Austin, Austin, TX, 78712, USA. Electronic address: bittner@austin.utexas.edu.
The University of Texas at Austin · USIndiana University Bloomington · USJohns Hopkins University · USUnit of Functional and Adaptive Biology · FR

Funding

A novel bioengineered technique to rapidly and permanently repair cut PNS nervesR01NS081063 · NINDS · UNIVERSITY OF TEXAS AT AUSTIN · PI BITTNER, GEORGE DAVIS · 2012 to 2016
$1.7M
NINDS NIH HHS R01 NS081063
6 · The paper itself

Abstract

backgroundNervous system injuries in mammals often involve transection or segmental loss of peripheral nerves. Such injuries result in functional (behavioral) deficits poorly restored by naturally occurring 1-2 mm/d axonal outgrowths aided by primary repair or reconstruction. "Neurorrhaphy" or nerve repair joins severed connective tissues, but not severed cytoplasmic/plasmalemmal extensions (axons) within the tissue. NEW

methodPEG-fusion consists of neurorrhaphy combined with a well-defined sequence of four pharmaceutical agents in solution, one containing polyethylene glycol (PEG), applied directly to closely apposed viable ends of severed axons.

resultsPEG-fusion of rat sciatic nerves: (1) restores axonal continuity across coaptation site(s) within minutes, (2) prevents Wallerian degeneration of many distal severed axons, (3) preserves neuromuscular junctions, (4) prevents target muscle atrophy, (5) produces rapid and improved recovery of voluntary behaviors compared with neurorrhaphy alone, and (6) PEG-fused allografts are not rejected, despite no tissue-matching nor immunosuppression. COMPARISON WITH EXISTING

methodsIf PEG-fusion protocols are not correctly executed, the results are similar to that of neurorrhaphy alone: (1) axonal continuity across coaptation site(s) is not re-established, (2) Wallerian degeneration of all distal severed axons rapidly occurs, (3) neuromuscular junctions are non-functional, (4) target muscle atrophy begins within weeks, (5) recovery of voluntary behavior occurs, if ever, after months to levels well-below that observed in unoperated animals, and (6) allografts are either rejected or not well-accepted.

conclusionPEG-fusion produces rapid and dramatic recovery of function following rat peripheral nerve injuries.

Indexed as

Neurosurgical ProceduresAllograftsAnimalsAxonsDisease Models, AnimalFemaleMaleNeuromuscular JunctionNeuroprotective AgentsPolyethylene GlycolsRandom AllocationRats, Sprague-DawleySciatic NerveSuture TechniquesWallerian DegenerationNeuroprotective AgentsPolyethylene GlycolsAllograftNeuromuscular junction re-innervationNeurorrhaphyPeripheral nerve injuryPolyethylene glycol fusionRat sciatic nerve repairWallerian degeneration

Identifiers

PMID30586569
PMCPMC6475191
OpenAlexW2906067567

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.